In recent years, the frequency of updates to medical treatment guidelines has increased significantly. From precision oncology and cardiovascular disease management to diabetes and autoimmune disorders, an expanding body of high-quality evidence-based medicine is reshaping clinical treatment paradigms.

For healthcare institutions, procurement departments, and pharmaceutical companies, clinical guidelines are not only essential tools for therapeutic decision-making but also key factors influencing drug procurement strategies and market demand.

As innovative therapies continue to emerge and real-world evidence accumulates, some medications that were once widely used are gradually moving away from core treatment pathways, while newer therapies are rapidly gaining prominence in guideline recommendations.

For pharmaceutical procurement management, understanding the logic behind guideline updates is becoming increasingly important for optimizing drug portfolios and improving resource allocation efficiency.

---

Why Do Clinical Guidelines Influence the Pharmaceutical Market?

Modern clinical guidelines are fundamentally evidence-based recommendation systems designed to help healthcare professionals select therapies that provide the greatest benefit to patients.

When new large-scale randomized controlled trials, long-term follow-up studies, or real-world evidence become available, guideline committees reassess a drug’s efficacy, safety, survival benefits, and overall clinical value.

If a treatment demonstrates superior outcomes in reducing mortality, delaying disease progression, or improving quality of life, its recommendation level may be upgraded. Conversely, if emerging evidence suggests limited efficacy, increased risks, or the availability of more effective alternatives, its clinical position may decline.

For healthcare institutions, changes in guideline recommendations often signal future shifts in clinical demand. Drug procurement is no longer based solely on historical utilization but increasingly aligned with current evidence-based practice.

As a result, guideline updates have become a significant factor influencing the lifecycle of pharmaceutical products.

---

Oncology: The Declining Role of Certain Traditional Chemotherapy Regimens

One of the most notable transformations in oncology over the past decade has been the rapid rise of targeted therapies and immunotherapies.

Taking non-small cell lung cancer (NSCLC) as an example, targeted therapies directed against driver mutations such as EGFR, ALK, ROS1, KRAS, and MET have increasingly become recommended first-line options.

In addition, PD-1/PD-L1 immunotherapies have evolved into standard treatment strategies for many patient populations.

Consequently, the utilization of some traditional platinum-based chemotherapy regimens has gradually declined.

It is important to note that conventional chemotherapy has not disappeared from clinical practice. Instead, its role is evolving:

• From first-line therapy to later-line treatment;
• From standalone therapy to part of combination regimens;
• From broad application to use in selected patient populations.

For hospital procurement teams, this shift indicates that demand growth for certain traditional chemotherapy agents may slow, while the importance of targeted therapies and immuno-oncology products continues to increase.

---

Cardiovascular Disease: Older Lipid-Lowering Agents Facing Replacement

The field of lipid management provides another clear example of guideline-driven change.

International guidelines increasingly emphasize the principle that “lower LDL-C is better,” shifting treatment goals from simply controlling cholesterol levels to reducing overall cardiovascular risk.

For high-risk and very-high-risk patients:

• High-intensity statin therapy remains the foundation of treatment;
• PCSK9 inhibitors have become important recommended options;
• siRNA-based lipid-lowering therapies are beginning to enter clinical practice.

At the same time, some older lipid-lowering agents with limited efficacy or relatively weaker outcome-based evidence are seeing reduced utilization in certain patient populations.

Procurement departments are increasingly focusing on therapies capable of helping patients achieve guideline-recommended LDL-C targets and improve long-term cardiovascular outcomes.

---

Infectious Diseases: The Clinical Scope of Some Antibiotics Continues to Narrow

Guideline updates in infectious diseases have also significantly influenced procurement structures.

As antimicrobial resistance becomes an increasingly serious global health challenge, clinical guidelines around the world emphasize:

• Antimicrobial stewardship programs;
• Rational antibiotic use;
• Reduction of unnecessary broad-spectrum antibiotic exposure.

As resistance rates continue to rise, some antibiotics that were previously used extensively are gradually losing their position in empirical treatment strategies.

Meanwhile, greater attention is being directed toward newer antimicrobial agents and precision approaches targeting resistant pathogens.

For hospital pharmacy and therapeutics committees, procurement strategies are gradually shifting from maintaining the broadest possible formulary to ensuring that antibiotic inventories align with actual clinical needs and resistance patterns.

---

Autoimmune Diseases: Biologics Are Reshaping Treatment Pathways

Rheumatologic and inflammatory diseases are undergoing similar transformations.

With the maturation of innovative therapies such as:

• TNF-α inhibitors;
• IL-17 inhibitors;
• IL-23 inhibitors;
• JAK inhibitors.

The treatment landscape has changed substantially.

Modern guidelines increasingly emphasize:

• Early intervention;
• Treat-to-target strategies;
• Earlier integration of advanced therapies when appropriate.

While traditional therapies such as glucocorticoids and non-specific immunosuppressants remain clinically important, their roles are being redefined.

In many cases, they are increasingly used as bridging therapies, adjunctive treatments, or options for selected patient populations rather than serving as the primary long-term treatment approach.

These changes demonstrate how continuous evidence generation can reshape therapeutic pathways and influence long-term pharmaceutical demand.

---

What Do Guideline Updates Mean for Procurement Decisions?

From a pharmaceutical management perspective, guideline changes often provide earlier signals of future clinical demand than market sales data.

When a drug’s recommendation level consistently declines, its long-term demand may gradually decrease even if current utilization remains stable.

Conversely, therapies that enter core guideline recommendations often experience steadily increasing clinical adoption over time.

As a result, modern pharmaceutical procurement is no longer focused solely on meeting current demand.

Instead, it requires forward-looking planning based on disease trends, evolving guideline recommendations, and future treatment paradigms.

Healthcare institutions are increasingly evaluating procurement decisions according to factors such as:

• Whether a product is included in core guideline recommendations;
• Whether its recommendation level has been upgraded;
• Whether it is supported by high-quality evidence;
• Whether it demonstrates meaningful clinical outcome benefits;
• Whether it aligns with reimbursement and health-economic trends;
• Whether it supports long-term disease management strategies.

Although many traditional therapies will not disappear entirely as guidelines evolve, their clinical positioning and procurement priority may gradually decline.

Meanwhile, innovative therapies capable of delivering meaningful clinical benefits and improving long-term patient outcomes are becoming increasingly important components of future pharmaceutical portfolios.

Hospitals, pharmacy departments, and procurement teams are therefore placing greater emphasis on continuously monitoring updates from international guideline organizations and integrating evidence-based recommendations into procurement planning.

This approach helps healthcare institutions optimize inventory structures, improve medication accessibility, and ensure that patients receive therapies supported by the latest clinical evidence.

---

DengYueMed’s Perspective

As global treatment guidelines continue to evolve, pharmaceutical procurement is transitioning from experience-based purchasing toward evidence-based strategic planning.

For pharmaceutical companies, wholesalers, distributors, and healthcare institutions, keeping pace with international guideline updates has become increasingly important for anticipating future market demand and identifying emerging therapeutic opportunities.

DengYueMed believes that future pharmaceutical supply chains will increasingly emphasize three core capabilities:

• Rapid response to guideline updates;
• Efficient allocation of innovative medicines;
• Professional pharmaceutical information support.

As precision medicine continues to advance, procurement decisions will rely not only on historical sales performance but also on the clinical value demonstrated through high-quality evidence and authoritative guideline recommendations.

Organizations capable of aligning pharmaceutical supply with evolving clinical practice will be better positioned to support healthcare providers while improving long-term operational efficiency and patient access to innovative therapies.

---

Conclusion

For healthcare institutions, pharmaceutical administration departments, and pharmaceutical industry professionals, paying attention to guideline changes not only helps optimize procurement structures but also helps them anticipate future treatment trends.

Against the backdrop of the continuous development of evidence-based medicine, the core of drug competition is gradually shifting from “whether it is effective” to “whether it can create greater clinical value.”

As a platform focused on global innovative drug developments and international pharmaceutical services, DengYueMed continuously tracks updates to international treatment guidelines, progress in innovative drug clinical research, and changes in global drug accessibility.

By providing professional pharmaceutical information support and insights into emerging treatment trends, DengYueMed helps healthcare institutions, industry partners, and patients better understand how evidence-based medicine is driving the continuous evolution of clinical treatment strategies, pharmaceutical procurement, and medication management.

Looking ahead, as guideline recommendations continue to evolve alongside advances in precision medicine, innovative therapeutics, and real-world evidence, pharmaceutical procurement will become increasingly evidence-driven and patient-centered.

Organizations that can rapidly adapt to guideline updates, optimize medicine portfolios, and support high-quality clinical care will be better positioned to meet the changing needs of modern healthcare systems.